20. Cost-Effectiveness of Implementing 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) for Adults Aged ≥19 Years with Underlying Conditions
20. 对患有基础疾病的19岁及以上成年人实施13价肺炎球菌结合疫苗(PCV13)的成本效益分析
期刊:Anatomy & Cell Biology
影响因子:1.2
doi:10.5115/acb.20.041
Altafulla, Juan J; Prickett, Joshua; Iwanaga, Joe; Dumont, Aaron S; Tubbs, R Shane; Siudela, Anthony; Khan, Afshin; Bateman, Marjorie E; Brown, Elizabeth R; Bershteyn, Anna; Karita, Helen C Stankiewicz; Johnston, Christine; Thorpe, Lorna; Kottkamp, Angelica; Neuzil, Kathleen; Laufer, Miriam K; Deming, Meagan; Paasche-Orlow, Michael K; Kissinger, Patricia J; Luk, Alfred; Paolino, Kristopher M; Paolino, Kristopher M; Landovitz, Raphael J; Hoffman, Risa; Schaafsma, Torin; Krows, Meighan L; Thomas, Katherine; Morrison, Susan; Kidoguchi, Lara; Wener, Mark H; Greninger, Alexander L; Huang, Meei-Li; Jerome, Keith; Wald, Anna; Wald, Anna; Celum, Connie; Chu, Helen Y; Baeten, Jared M; Lauth, Michael J; Cook, Greg; Silio, Margarita; Himmelfarb, Sarah Talia; Bond, Nell; Okoli, Adaora; Schieffelin, John; Shaffer, Jeffrey; Samuels, Robert J; Engel, Emily J; Kobayashi, Miwako; Stoecker, Charles; Xing, Wei; Cho, Bo-Hyun; Pilishvili, Tamara